Edap Tms (NASDAQ:EDAP) Rating Lowered to Sell at Zacks Investment Research
According to Zacks, “EDAP TMS S.A. develops, produces, markets and distributes minimally invasive medical devices, primarily for the treatment of urological diseases. They currently produce and market devices for treatment of benign prostate hyperplasia and urinary tract stones. They are also developing a third range of products for minimally invasive destruction of certain types of tumors. “
Several other equities research analysts also recently issued reports on the company. ValuEngine raised YY from a sell rating to a hold rating in a report on Friday, June 7th. TheStreet downgraded Timkensteel from a c- rating to a d+ rating in a report on Monday, June 17th. Finally, HC Wainwright set a $4.00 price target on Uranium Energy and gave the company a buy rating in a report on Tuesday, June 11th.
Edap Tms (NASDAQ:EDAP) last announced its quarterly earnings results on Wednesday, May 15th. The medical equipment provider reported $0.01 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.01. Edap Tms had a negative return on equity of 1.13% and a negative net margin of 0.36%. The business had revenue of $11.50 million during the quarter, compared to the consensus estimate of $13.25 million. Equities research analysts forecast that Edap Tms will post 0.08 EPS for the current year.
A hedge fund recently raised its stake in Edap Tms stock. Fosun International Ltd raised its holdings in shares of Edap Tms SA (NASDAQ:EDAP) by 45.9% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 363,485 shares of the medical equipment provider’s stock after purchasing an additional 114,342 shares during the quarter. Fosun International Ltd owned approximately 1.25% of Edap Tms worth $1,072,000 at the end of the most recent reporting period. 10.31% of the stock is currently owned by hedge funds and other institutional investors.
About Edap Tms
EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases worldwide. The company operates in two divisions: High Intensity Focused Ultrasound (HIFU), and Urology Devices and Services (UDS).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Edap Tms Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edap Tms and related companies with MarketBeat.com's FREE daily email newsletter.